Search This Blog

Tuesday, September 29, 2026

Iovance record Q2 2026 product revenue of $99.3 m, ups 2026 revenue guidance to $410–$420 million

 


  • Guidance raised from $350–$370 million on stronger-than-expected U.S. demand for Amtagvi and Proleukin.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)